NCT06554600View on ClinicalTrials.gov

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2028

Conditions
Refractory or Relapsed Diffuse Large B Cell Lymphoma
Interventions
DRUG

Zanubrutinib

160mg bid PO（d0-d20）

DRUG

Polatuzumab Vedotin

Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.

DRUG

Bendamustine

Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.

DRUG

Rituximab

Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.

Trial Locations (1)

310009

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER